Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bc788bb66aee6eb784e30f3818a910219> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bc788bb66aee6eb784e30f3818a910219 NCIT_P378 "NCI" @default.
- Bc788bb66aee6eb784e30f3818a910219 type Axiom @default.
- Bc788bb66aee6eb784e30f3818a910219 annotatedProperty IAO_0000115 @default.
- Bc788bb66aee6eb784e30f3818a910219 annotatedSource NCIT_C157062 @default.
- Bc788bb66aee6eb784e30f3818a910219 annotatedTarget "A recombinant, humanized, agonistic, tetravalent monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, INBRX-109 specifically binds to exactly four DR5 receptors per molecule, which mimics the interaction of DR5 with its natural ligand TRAIL. This activates DR5 and the death receptor signaling pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. Utilizing a tetravalent monoclonal antibody may overcome the challenge of generating effective DR5 clustering while avoiding toxicities associated with anti-drug antibody (ADA) hyper-clustering. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis." @default.